- Barrons.com•13 hours ago
Hopes were high for MannKind (MNKD) when its inhaled insulin Afrezza was approved by the FDA more than two years ago. At the time, Barron's warned that it was time to dump MannKind's shares, something that now seems prescient, as its shares have since tumbled 95%. MannKind found a partner in Sanofi (SNY), only to get dumped in early 2016, and has since been forced to sell property to raise cash.
- GlobeNewswire•7 days ago
VALENCIA, Calif., Feb. 21, 2017-- MannKind Corporation today confirmed that it received $16.7 million on February 17, 2017, upon closing the sale of real estate owned by the Company in Valencia, California, ...
- 24/7 Wall St.•18 days ago
Judging by the most shorted stocks traded on the Nasdaq in late January, those short sellers who remained active continued to be cautious.
MNKD : Summary for MannKind Corporation - Yahoo Finance
MannKind Corporation (MNKD)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||0.48 x 15100|
|Ask||0.50 x 400|
|Day's Range||0.51 - 0.54|
|52 Week Range||0.41 - 2.24|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.13|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|